MTRI

13.66510.36%
LS

Laura Sandler

Chief Operating Officer

Ms. Laura Sandler is Chief Operating Officer of Oruka Therapeutics, Inc. from July 2025. Ms. Laura Sandler was Senior Vice President of Strategic Operations of Kelonia Therapeutics, Inc. until 2024. Ms. Sandler is Independent Director of Mentari Therapeutics, Inc. She was Senior Vice President of Operations at Oruka Therapeutics, Inc until Julu 2025. Prior to that, she built and led the development operations team at CRISPR Therapeutics and was responsible for clinical execution for the entirety of the corporate pipeline, including CASGEVY™, the first approved CRISPR-based medicine worldwide. She also led the development operations team at bluebird bio from IND-enabling work through human proof of concept for LYFGENIA™, the first viral-based gene therapy approved for sickle cell patients. In her career she held roles in project management and clinical operations at Ventrus Biosciences, Novartis,Quintiles, IQVIA and MedImmune. She earned her master’s degree in public health from Boston University and has a bachelor’s degree from MIT.

Positions